NEW YORK (GenomeWeb) – Exosome Diagnostics announced today that it has partnered with Amgen to develop a liquid biopsy test.
Under the terms of the deal, the companies will use Exosome's technology to identify a potential liquid biopsy diagnostic that may be used in Amgen's drug development processes. Additional terms of the arrangement were not disclosed.